Legend of Xiangjiang Tycoon Chapter 507

"The Legend of Hong Kong Tycoon (

"Boss, I don't think it is necessary for Xiangjiang to stay in the R&D center. The R&D center in Silicon Valley can do research and development. In fact, the research and development of Xiangjiang Semiconductor has always been in a backward state. In this case, I think it is good for Xiangjiang to only do OEM!" Zhang Zhong said a.

Li Zhiwen glanced at Zhang Zhongmou and said nothing.

Zhang Zhongmou only looks at the technical and economic aspects, while Li Zhiwen takes into account state relations.

Although the beautiful country and the mainland are in the honeymoon period, the beautiful country has to be disintegrated all the time.

Furthermore, if Li Zhiwen wants to engage in semiconductors, he can directly invest in existing companies.

Of course, Li Zhiwen had no way to tell Zhang Zhongmou these words, because he couldn't understand it, and it was difficult for Li Zhiwen to know his position.

"I want to turn the company into a dual system, with two R&D centers. Although the semiconductor technology of the beautiful country is very advanced, don't underestimate the wisdom of the yellow race. I want to use the R&D center in Hong Kong as a training and experimental base for the entire group. , there are suitable talents and technologies to be imported into Silicon Valley!" Li Zhiwen explained casually.

When Zhang Zhongmou heard Li Zhiwen's explanation, although he didn't understand it, he didn't say anything more. After all, the company was Li Zhiwen's company, so he couldn't say anything more.

"Then if you take out equity incentives, do you take companies in Silicon Valley?" Zhang Zhongmou said.

"Of course, do the companies in Xiangjiang like these people? I don't care!" Li Zhiwen pretended.

"I don't think they will, so it's better to use Silicon Valley companies as equity incentives!" Zhang Zhongmou said.

Just kidding, how can Xiangjiang's companies be compared with Silicon Valley companies, and these talents are all aimed at laboratories in Silicon Valley. For them, Xiangjiang's companies, what is that, a factory?

And this is also in Li Zhiwen's mind. Li Zhiwen never wanted to include Hong Kong companies in the equity incentives, there is no need.

In Li Zhiwen's view, that is what Li Zhiwen likes the most, and it is also where he will invest the most in the future.

As for Silicon Valley companies, Li Zhiwen feels that if he does not engage in equity incentives, there may be a large number of employee turnover, and he may also be targeted by the upper echelons of the lighthouse country.

After all, how can such a high-precision semiconductor technology be mastered by a Chinese alone.

"Okay, you go down and come up with a plan in a while, and I'll give instructions!" Li Zhiwen said.

"Yes, boss!" Zhang Zhongmou finished and left the office.

And Li Zhiwen looked at the busy workers downstairs, and after thinking about it, he finally left HKSMC and went to the Mars Fund Company not far away.

At this time, although Li Zhiwen did not come to the Mars Fund much, he also knew that the Mars Fund participated in the angel investment of many Silicon Valley startups.

These investments were all low-value and small investments, so Curatos Blanc did not inform Li Zhiwen in advance, but only wrote a report to Li Zhiwen before the investment.

I listened to Li Zhiwen's opinion, but at this time Li Zhiwen didn't know much about the unknown companies in Silicon Valley, so he didn't interfere too much.

However, these investments have more success and fewer failures. The reason is that after the investment in the angel round, Curatos Blanc will withdraw in the second and third rounds, so basically there will not be too many failures. .

What's more important is that Curatos Blanc will do a detailed analysis before each investment, which is why Li Zhiwen is relieved.

"Boss!" "Boss!" "Boss!" The staff of the Mars Fund shouted to Li Zhiwen one by one, and Li Zhiwen responded with a smile one by one.

Although Li Zhiwen doesn't come often, every employee knows him for no other reason. There is a photo of Li Zhiwen in Curatos Blanc's office.

"Boss!" Curatos Blanc shouted.

"Kuratos, you are getting more and more energetic!" Li Zhiwen said.

"It's all because of the boss!" Li Zhiwen pointed at Curatos Blanc with his finger.

In this way, Curatos Blanc followed Li Zhiwen to the office.

"Kuratos, if you have to call me for something, tell me!" Li Zhiwen said.

Curatos Blanc handed a document in his hand to Li Zhiwen and said, "Boss, look at this!"

Li Zhiwen picked up the document and glanced at it, then stared at Curatos Blanc again.

The document reads "About Amgen's Shareholding Proposal."

The reason why Li Zhiwen will look at Curatos Blanc is because Curatos Blanc has always been interested in the Internet industry before, how can he jump to the bio-manufacturing industry now.

The name of the Amgen company, Li Zhiwen, has been heard before. In the previous life, Li Zhiwen had seen someone who used the drugs of the Amgen company.

The Internet and biopharmaceuticals are the industries that make the fastest money in the future.

Unexpectedly, after Curatos Blanc had set up in the Internet industry, he turned his attention to biopharmaceutical companies.

At this time, the biopharmaceutical companies in the lighthouse country are developing rapidly. There are not a few pharmaceutical giants. The first is not Johnson & Johnson, which is the first in the future, but Merck, which has a market value of more than 200 billion US dollars, and Johnson & Johnson is the second. .

Next, are Eli Lilly, Bristol-Myers Squibb, Pfizer, Wyeth, Abbott and other companies.

Founded in 1886, Johnson & Johnson is the world's second largest healthcare and consumer care products company with diversified products.

In 1886, Johnson and his two brothers in New Bruswick, New Jersey, USA, jointly created a new business - the production of sterile surgical dressings, and officially created the Johnson & Johnson Company.

They employ 14 employees and have always maintained a leading position in the industry.

With the expansion and development of the business, Johnson & Johnson has successively established new international companies in the Americas, Europe, Africa, Asia and Australia since the 1920s, producing high-quality health products and promoting the healthy development of the world.

After more than 100 years of unremitting efforts and innovation, Johnson & Johnson has established more than 170 branches in 35 countries around the world, and its products are sold in 115 countries and regions. With more than 14,000 employees, it has become the most comprehensive and widely distributed health care product manufacturer and related service provider in the world, producing and selling products involving consumer products and personal care products, pharmaceutical products and medical equipment and diagnostics product market, etc.

Later, Johnson & Johnson went deep into various families in the mainland and acquired many brands. Those who didn't know it thought that Johnson & Johnson was a Chinese company, but in fact, people have always been old and beautiful.

The current market value of this company is about more than ten billion US dollars. Think about how high it is. You must know that Ibm, the Internet giant with the highest market value in the lighthouse country, has a market value of more than 30 billion US dollars.

Founded in 1668, the Merck Group has a history of about 320 years and is headquartered in Darmstadt, Germany. The group is mainly committed to innovative pharmaceuticals, life sciences and cutting-edge functional material technologies, and is driven by technology , creating value for patients and customers.

In 1668, Frederick Jacob Merck acquired the Angel Pharmacy in Darmstadt, opening the way for the development of the business. The Angel Pharmacy also became the origin of the family company.

In 1816, Heinrich Emmanuel Merck took over Angel's Pharmacy and began to develop it into a global company. He started industrial-scale production for the first time. In the medical world, he laid the foundation for the transition from simple manual skills to technological production.

In 1827, Heinrich Emmanuel Merck started industrial mass production.

In 1900, Merck had branches or representatives on all continents around the world.

In 1904, it was listed as a medical drug product for the first time; started the research on liquid crystal materials.

In 1917, the subsidiary in the United States was confiscated, and Merck and Merck became independent.

Look at the good things that Laomei did in the past, she would take it by accident at that time, not to mention later generations.

The Merck subsidiary, which was confiscated by the old United States, changed its name to Merck and continued to operate, so that Merck was called Merck in North America and Merck outside North America.

Then Merck continued to develop, and eventually developed into the leader of the lighthouse biopharmaceutical company today, with a market value of more than 15 billion US dollars, which is 2 billion US dollars higher than the market value of Johnson & Johnson.

Speaking of Eli Lilly, it's a bit dramatic.

In 1876, Colonel Eli Lilly founded Eli Lilly and Company in Indianapolis, a city in the American Midwest state of Indiana.

As a 38-year-old pharmacist and American Civil War veteran, Lilly Upper School was very disappointed with poorly formulated and often ineffective drugs.

Therefore, he made the following promise to himself and the society: he would set up a pharmaceutical company to produce the highest quality products, and his company would only produce medicines that require a doctor's prescription, not fake and inferior products blindly promoted by charlatans.

Eli Lilly's products are developed and produced using state-of-the-art science and technology. Despite his business's smooth sailing, Colonel Eli Lilly was dissatisfied with traditional methods of drug monitoring.

In 1886, he hired a young chemist as a full-time researcher, conducting quality inspections by applying and developing the latest scientific techniques.

Together, they laid the foundation for Lilly's legacy of working first to improve the quality of existing products, and then to inventing and developing new and better medicines.

Later, Colonel Eli Lilly's son and two grandsons served as the company's president. Each of them has made a unique contribution to the management of the company.

These management styles gradually formed the company's culture, in which employees were regarded as the most valuable asset and at the core of the company's operating philosophy.

Today, Eli Lilly has more than 30,000 employees worldwide, covering more than 30 countries and regions around the world. It is the third largest pharmaceutical company in the beautiful country.

Bristol-Myers Squibb's predecessor was the Clinton Pharmaceutical Company founded in Clinton, New York in 1887 by William M. Bristol and John R. Meyers, which was renamed Bristol Meyers in 1898 , In 1900, the company was registered as a joint-stock company and turned its business focus to the wholesale and retail of pharmaceuticals. Since then, the company has developed rapidly.

In 1924, the company's total profits reached one million dollars for the first time, and its products were sold in twenty-six countries.

Good performance brought a series of changes, and in 1929, the company's stock was listed in New York.

In 1943, the company acquired the Cheplin Biotechnology Laboratory and mass-produced penicillin and antibiotics for the American troops.

After World War II, the company continued to grow, while at the same time undertaking large-scale mergers.

This included the acquisition of the Wig Manufacturers Company in 1959. There are also household products manufacturer Drackett Company (1965), surgical products company Zimmer Manufacturing Company (1972), dental products manufacturer Unitek Company (1978) and so on.

At the same time, the company has also obtained the right to sell anti-cancer drugs developed by the National Institute of Health Research and other units.

From 1974 to 1980, the company had 11 new anti-cancer drugs put into the market, bringing the company a profit of 200 million US dollars.

The Bristol-Myers Squibb Company was founded in Brooklyn, New York in 1856 by Dr. Edward R. Bristol-Myers Squibb, mainly producing pure ether.

In 1905, Bristol-Myers Squibb's son sold the company to Merck & Co founder Theodore Wick.

Between 1909 and 1929, the company's annual sales soared from $414,000 to $130 million. During World War II, the company became a major supplier of morphine and penicillin.

In 1946, the company expanded to Latin America, Europe and other places, setting up production plants in Mexico, Italy and Argentina. 1971 ~www.mtlnovel.com~ changed its name to Bristol-Myers Squibb Corporation. In 1975, annual sales reached 1 billion US dollars.

Pfizer was founded in 1849. In the early days, Pfizer was a chemical company whose main business was the production of chemical products. Drugs, as a type of chemicals, also belonged to the company's business scope.

The Civil War that broke out in 1861 gave Pfizer an opportunity to develop. During the war, Pfizer provided a large amount of medicines to the Union Army. With the progress of the war, the company developed rapidly and became one of the largest chemical manufacturers in the United States.

After the Civil War, Pfizer's main product was citric acid. Until Sir Fleming discovered penicillin in 1928, Pfizer began to intervene in the production of antibiotics, and gradually shifted the focus of the company to the field of antibiotics. After that, Pfizer carried out a fermentation process. In-depth research, and its use in the production of citric acid and penicillin, the industry generally agrees that Pfizer is one of the pioneers in the development of fermentation technology.

The Second World War gave Pfizer another opportunity to develop. Pfizer was the only company that used fermentation technology to produce penicillin at that time. It not only produced a large amount of penicillin but also had a very low production cost. It provided a large number of relatively cheap penicillin products to the US military. , the company also took advantage of this opportunity to expand rapidly.

After the war, Pfizer further strengthened the production and research and development of drugs, and successfully developed the broad-spectrum antibiotic oxytetracycline in 1951.

Since then, the successful development of tetracycline, piroxicam and other drugs has brought huge economic benefits to Pfizer. Many of these drugs have become classic clinical drugs, and many of Pfizer's R&D cases have thus become classic cases of drug design.

In this way, Pfizer has developed rapidly. Although these companies have projects in the rankings, except for the top two, the others are not much different.

Chapter end